Skip to main content

Sarcoidosis clinical trials at UC Davis
1 research study open to eligible people

  • Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

    open to eligible people ages 18-75

    This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.

    Sacramento, California and other locations

Last updated: